Verdict in the case of therapies versus eosinophils: The jury is still out

Journal of Allergy and Clinical Immunology

Volumn 113, Issue 1, 2004, Pages 3-9

  Bochner, Bruce S ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS ASTHMA AND ALLERGY CENTER   (United States)

Author keywords

Asthma; Eosinophil; Phenotype; Targets; Therapy

Indexed keywords

BETA1 INTEGRIN; CD11B ANTIGEN; CD15 ANTIGEN; CD24 ANTIGEN; CD28 ANTIGEN; CD52 ANTIGEN; CD53 ANTIGEN; CD86 ANTIGEN; CD9 ANTIGEN; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; COMPLEMENT COMPONENT C3 RECEPTOR; COMPLEMENT COMPONENT C3A RECEPTOR; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C5A RECEPTOR; FAS ANTIGEN; GAMMA INTERFERON; HERMES ANTIGEN; IMMUNOGLOBULIN RECEPTOR; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 5; LEUKOCYTE ANTIBODY; LEUKOTRIENE C4; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; THROMBOCYTE ACTIVATING FACTOR RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ASTHMA; CELL SURFACE; DISEASE COURSE; DOWN REGULATION; EOSINOPHIL; EOSINOPHILIA; HUMAN; INFLAMMATION; MEDICAL LITERATURE; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; REDUCTION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

EID: 0346869043     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2003.09.046     Document Type: Review

References (97)

1. Weller PF. Human eosinophils. J Allergy Clin Immunol 1997;100:283-7.
2. Rothenberg ME. Mechanisms of disease: eosinophilia. N Engl J Med 1998;338:1592-600.
3. Menzies-Gow A. Robinson DS. Eosinophils, eosinophilic cytokines (interleukin-5), and antieosinophilic therapy in asthma. Curr Opin Pulm Med 2002;8:33-8.
4. Kay AB, Menzies-Gow A. Eosinophils and intedeukin-5: the debate continues. Am J Respir Crit Care Med 2003;167:1586-7.
5. Foster PS, Hogan SP, Yang M, Mattes J, Young IG, Matthaei KI, et al. Interleukin-5 and eosinophils as therapeutic targets for asthma. Trends Mol Med 2002;8:162-7.
6. Gleich GJ. Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol 2000;105:651-63.
7. Kingham PJ, Costello RW, McLean WG. Eosinophil and airway nerve interactions. Pulm Pharmacol Ther 2003;16:9-13.
8. Kita H, Adolphson CR, Gleich GJ. Biology of eosinophils. In: Adkinson NF Jr, Yunginger JW, Busse WW, Bochner BS, Holgate ST, Simons FER, eds. Allergy: principles and practice. 6th ed. Philadelphia: Mosby; 2003. p. 305-32.
9. Barnes P. New directions in allergic diseases: mechanism-based anti-inflammatory therapies. J Allergy Clin Immunol 2000;106:5-16.
10. Canning BJ. Modeling asthma and COPD in animals: a pointless exercise? Curr Opin Pharmacol 2003;3:244-50.
11. Flavahan NA, Slifman NR, Gleich GJ, Vanhoutte PM. Human eosinophil major basic protein causes hyperreactivity of respiratory smooth muscle. Am Rev Respir Dis 1988;138:685-8.
12. Gundel RH, Letts LG, Gleich GJ. Human eosinophil major basic protein induces airway constriction and airway hyperresponsiveness in primates. J Clin Invest 1991;87:1470-3.
13. Lefort J, Nahori MA, Ruffie C, Vargaftig BB, Pretolani M. In vivo neutralization of eosinophil-derived major basic protein inhibits antigen-induced bronchial hyperreactivity in sensitized guinea pigs. J Clin Invest 1996;97:1117-21.
14. Zimmermann N, Hershey GK, Foster PS, Rothenberg ME. Chemokines in asthma: cooperative interaction between chemokines and IL-13. J Allergy Clin Immunol 2003;111:227-43.
15. Wills-Karp M, Luyimbazi J, Xu XY, Schofield B, Neben TY, Karp CL, et al. Interleukin-13: central mediator of allergic asthma. Science 1998;282:2258-61.
16. Bousquet J, Chanez P, Lacoste JY, Barneon G, Ghavanian N, Enander I, et al. Eosinophilic inflammation in asthma. N Engl J Med 1990;323:1033-9.
17. Jatakanon A, Lim S, Barnes PJ. Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med 2000;161:64-72.
18. Filley WV, Holley KE, Kephart GM, Gleich GI. Identification by immunofluorescence of eosinophil granule major basic protein in lung tissues of patients with bronchial asthma. Lancet 1982;2:11-5.
19. Agosti JM, Altman LC, Ayars GH, Loegering DA, Gleich GJ, Klebanoff SJ. The injurious effect of eosinophil peroxidase, hydrogen peroxide, and halides on pneumocytes. J Allergy Clin Immunol 1987;79:496-504.
20. Pizzichini E, Pizzichini MM, Efthimiadis A, Dolovich J, Hargreave FE. Measuring airway inflammation in asthma: eosinophils and eosinophilic cationic protein in induced sputum compared with peripheral blood. J Allergy Clin Immunol 1997;99:539-44.
21. Gleich GJ, Hunt LW, Bochner BS, Schleimer RP. Glucocorticoid effects on human eosinophils. In: Schleimer RP, Busse WW, O'Byrne P, eds. Inhaled glucocorticoids in asthma: mechanisms and clinical actions. New York: Marcel Dekker, Inc; 1996. p. 279-308.
22. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002;360:1715-21.
23. Ebisawa M, Schleimer RP, Bickel C, Bochner BS. Phenotyping of purified human peripheral blood eosinophils using the blind panel mAb. In: Schlossman S, Boumsell L, Gilks W, Harlan J, Kishimoto T, Morimoto C, et al, eds. Leukocyte typing V: white cell differentiation antigens. New York: Oxford University Press; 1995. p. 1036-8.
24. Temple R, Allen E, Fordham J, Phipps S, Schneider HC, Lindauer K, et al. Microarray analysis of eosinophils reveals a number of candidate survival and apoptosis genes. Am J Respir Cell Mol Biol 2001;25:425-33.
25. Tachimoto H, Bochner BS. The surface phenotype of human eosinophils. Chem Immunol 2000;76:45-62.
26. Woerly G, Roger N, Loiseau S, Dombrowicz D, Capron A, Capron M. Expression of CD28 and CD86 by human eosinophils and role in the secretion of type 1 cytokines (interleukin 2 and interferon gamma): inhibition by immunoglobulin A complexes. J Exp Med 1999;190:487-95.
27. Kikly KK, Bochner BS, Freeman S, Tan KB, Gallagher KT, D'Alessio K, et al. Identification of SAF-2, a novel siglec expressed on eosinophils, mast cells and basophils. J Allergy Clin Immunol 2000;105:1093-100.
28. Nutku E, Aizawa H, Hudson SA, Bochner BS. Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis. Blood 2003;101:5014-20.
29. Nagata K, Hirai H, Tanaka K, Ogawa K, Aso T, Sugamura K, et al. CRTH2, an orphan receptor of T-helper-2-cells, is expressed on basophils and eosinophils and responds to mast cell-derived factor(s). FEBS Lett 1999;459:195-9.
30. Gervais FG, Cruz RPG, Chateanuneuf A, Gale S, Sawyer N, Nantel F, et al. Selective modulation of chemokinesis, degranulation, and apoptosis in eosinophils through the PGD2 receptors CRTH2 and DP. J Allergy Clin Immunol 2001;108:982-8.
31. Tedla N, Bandeira-Melo C, Tassinari P, Sloane DE, Samplaski M, Cosman D, et al. Activation of human eosinophils through leukocyte immunoglobulin-like receptor 7. Proc Natl Acad Sci U S A 2003;100:1174-9.
32. Bochner BS, Schroeder J. Basophils. In: Austen KF, Frank MM, Atkinson JP, Cantor H, eds. Samter's immunological diseases. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 244-53.
33. Bochner BS, Schleimer RP. Mast cells, basophils, and eosinophils: distinct but overlapping pathways for recruitment. Immunol Rev 2001;179:5-15.
34. Leckie MJ, Brinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000;356:2144-8.
35. Buttner C, Lun A, Splettstoesser T, Kunkel G, Renz H, Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions. Eur Respir J 2003;21:799-803.
36. Bryan SA, O'Connor BJ, Matti S, Leckie MJ, Kanabar V, Khan J, et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000;356:2149-53.
37. O'Byrne PM, Inman MD, Parameswaran K. The trials and tribulations of IL-5, eosinophils, and allergic asthma. J Allergy Clin Immunol 2001;108:503-8.
38. Kips JC, O'Connor BJ, Langley SJ, Woodcock A, Kerstjens HA, Postma DS, et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 2003;167:1655-9.
39. Mattes J, Yang M, Mahalingam S, Kuehr J, Webb DC, Simson L, et al. Intrinsic defect in T cell production of interleukin (IL)-13 in the absence of both IL-5 and eotaxin precludes the development of eosinophilia and airways hyperreactivity in experimental asthma. J Exp Med 2002;195:1433-44.
40. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003;167:199-204.
41. Menzies-Gow A, Flood-Page P, Sehmi R, Burman J, Hamid Q, Robinson DS, et al. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol 2003;111:714-9.
42. Liu LY, Sedgwick JB, Bates ME, Vrtis RF, Gern JE, Kita H, et al. Decreased expression of membrane IL-5 receptor alpha on human eosinophils: I. Loss of membrane IL-5 receptor alpha on airway eosinophils and increased soluble IL-5 receptor alpha in the airway after allergen challenge. J Immunol 2002;169:6452-8.
43. Liu LY, Sedgwick JB, Bates ME, Vrtis RF, Gern JE, Kita H, et al. Decreased expression of membrane IL-5 Receptor alpha on human eosinophils: II. IL-5 down-modulates its receptor via a proteinase-mediated process. J Immunol 2002;169:6459-66.
44. Gregory B, Kirchem A, Phipps S, Gevaert P, Pridgeon C, Rankin SM, et al. Differential regulation of human eosinophil IL-3, IL-5, and GM-CSF receptor alpha-chain expression by cytokines: IL-3, IL-5, and GM-CSF down-regulate IL-5 receptor alpha expression with loss of IL-5 responsiveness, but up-regulate IL-3 receptor alpha expression. J Immunol 2003;170:5359-66.
45. Phipps S, Flood-Page P, Menzies-Gow A, Wangoo A, Barnes N, Barkans J, et al. Anti-IL-5 (mepolizumab) reduces the expression of tenascin, procollagen III and lumican in the reticular basement membrane of human atopic asthmatics [abstract]. J Allergy Clin Immunol 2003;111(suppl):S278.
46. Rizzo CA, Yang R, Greenfeder S, Egan RW, Pauwels RA, Hey JA. The IL-5 receptor on human bronchus selectively primes for hyperresponsiveness. J Allergy Clin Immunol 2002;109:404-9.
47. Sugiyama K, Cheng G, Aoki Y, Fukuda T. Anti-IL-5 receptor antibody, but not anti-IL-5 antibody, inhibits airway hyperresponsiveness in murine model of chronic asthma [abstract]. Am J Respir Crit Care Med 2002;167:A494.
48. Yu C, Cantor AB, Yang H, Browne C, Wells RA, Fujiwara Y, et al. Targeted deletion of a high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo. J Exp Med 2002;195:1387-95.
49. Kudlacz E, Whitney C, Andresen C, Duplantier A, Beckius G, Chupak L, et al. Pulmonary eosinophilia in a murine model of allergic inflammation is attenuated by small molecule a4β1 antagonists. J Pharmacol Exp Ther 2002;301:747-52.
50. Bochner BS. Leukocyte recruitment in allergic pulmonary inflammation. In: Eissa T, Huston D, eds. Therapeutic targets of airway inflammation. New York: Marcel Dekter, Inc; 2003. p. 223-47.
51. Koo GC, Shah K, Ding GJ, Xiao J, Wnek R, Doherty G, et al. A small molecule very late antigen-4 antagonist can inhibit ovalbumin-induced lung inflammation. Am J Respir Crit Care Med 2003;167:1400-9.
52. Renzetti L, Tannu S, Connaughton S, Sidduri A, Tilley J, Cavallo G. Attenuation of airway inflammation and hyperresponsiveness in murine and primate models of asthma by Ro 27-0608, a dual α4β1/α 4β7 integrin antagonist [abstract]. Am J Respir Crit Care Med 2003;167:A640.
53. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348:15-23.
54. Mishra A, Hogan SP, Lee JJ, Foster PS, Rothenberg ME. Fundamental signals that regulate eosinophil homing to the gastrointestinal tract. J Clin Invest 1999;103:1719-27.
55. Rothenberg ME. Eosinophilic gastrointestinal disorders. J Allergy Clin Immunol 2004. In press.
56. Gauvreau GM, Becker AB, Boulet L-P, Chakir J, Fick RB, Greene WL, et al. The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjcts with atopic asthma. J Allergy Clin Immunol 2003. In press.
57. Wegner CD, Gundel RH, Reilly P, Haynes N, Letts LG, Rothlein R. Intercellular adhesion molecule-1 (ICAM-1) in the pathogenesis of asthma. Science 1990;247:456-9.
58. Davenpeck KL, Brummet ME, Sterbinsky SA, Mayer RJ, Bochner BS. Activation of human leukocytes reduces surface P-selectin glycoprotein ligand-1 (PSG1-1, CD162) and adhesion to P-selectin in vitro. J Immunol 2000;165:2764-72.
59. Strauss EC, Larson KA, Brenneise I, Foster CS, Larsen GR, Lee NA, et al. Soluble P-selectin glycoprotein ligand 1 inhibits ocular inflammation in a murine model of allergy. Invest Ophthalmol Vis Sci 1999;40:1336-42.
60. Broide DH, Humber D, Sullivan S, Sriramarao P. Inhibition of eosinophil rolling and recruitment in P-selectin-and intracellular adhesion molecule-1-deficient mice. Blood 1998;91:2847-56.
61. Pereira S, Clark T, Darby Y, Salib R, Salagean M, Hewitt L, et al. Effects of anti-eotaxin monoclonal antibody CAT-213 on allergen-induced rhinitis [abstract]. J Allergy Clin Immunol 2003;111(suppl):S268.
62. White JR, Lee JM, Dede K, Imburgia CS, Jurewicz AJ, Chan G, et al. Identification of potent, selective non-peptide CC chemokine receptor-3 antagonist that inhibits eotaxin-, eotaxin-2-, and monocyte chemotactic protein-4-induced eosinophil migration. J Biol Chem 2000;275:36626-31.
63. Dhanak D, Christmann LT, Darcy MG, Keenan RM, Knight SD, Lee J, et al. Discovery of potent and selective phenylalanine derived CCR3 receptor antagonists. Bioorg Med Chem Lett 2001;11:1445-50.
64. Warrior U, McKeegan EM, Rottinghaus SM, Garcia L, Traphagen L, Grayson G, et al. Identification and characterization of novel antagonists of the CCR3 receptor. J Biomol Screen 2003;8:324-31.
65. Hirai H, Tanaka K, Yoshie O, Ogawa K, Kenmotsu K, Takamori Y, et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 2001;193:255-61.
66. Mitsumori S, Tsuri T, Honma T, Hiramatsu Y, Okada T, Hashizume H, et al. Synthesis and biological activity of various derivatives of a novel class of potent, selective, and orally active prostaglandin D2 receptor antagonists. 2. 6,6-Dimethylbicyclo[3.1.1]heptane derivatives. J Med Chem 2003;46:2446-55.
67. Culley FJ, Fadlon EJ, Kirchem A, Williams TJ, Jose PJ, Pease JE. Proteoglycans are potent modulators of the biological responses of eosinophils to chemokines. Eur J Immunol 2003;33:1302-10.
68. DiScipio RG, Daffern PJ, Jagels MA, Broide DH, Sriramarao P. A comparison of C3a and C5a-mediated stable adhesion of rolling eosinophils in postcapillary venules and transendothelial migration in vitro and in vivo. J Immunol 1999;162:1127-36.
69. Matsumoto K, Appiah-Pippim J, Schleimer RP, Bickel CA, Beck LA, Bochner BS. CD44 and CD69 represent different types of cell surface activation markers for human eosinophils. Am J Respir Cell Mol Biol 1998;18:860-6.
70. Katoh S, Matsumoto N, Kawakita K, Tominaga A, Kincade PW, Matsukura S. A role for CD44 in an antigen-induced murine model of pulmonary eosinophilia. J Clin Invest 2003;111:1563-70.
71. O'Reilly M, Alpert R, Jenkinson S, Gladue RP, Foo S, Trim S, et al. Identification of a histamine H4 receptor on human eosinophils - role in eosinophil chemotaxis. J Recept Signal Transduct Res 2002;22:431-48.
72. Floyd H, Ni J, Cornish AL, Zeng Z, Liu D, Carter KC, et al. Siglec-8: a novel eosinophil-specific member of the immunoglobulin superfamily. J Biol Chem 2000;275:861-6.
73. Crocker PR, Varki A. Siglecs in the immune system. Immunology 2001;103:137-45.
74. Foussias G, Yousef GM, Diamandis EP. Molecular characterization of a Siglec-8 variant containing cytoplasmic tyrosine-based motifs, and mapping of the Siglec-8 gene. Biochem Biophys Res Commun 2000;278:775-81.
75. Aizawa H, Plitt J, Bochner BS. Human eosinophils express two siglec-8 splice variants. J Allergy Clin Immunol 2002;109:176.
76. Sayos J, Wu C, Morra M, Wang N, Zhang X, Allen D, et al. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature 1998;395:462-9.
77. Yousef GM, Ordon MH, Foussias G, Diamandis EP. Genomic organization of the siglec gene locus on chromosome 19q13.4 and cloning of two new siglec pseudogenes. Gene 2002;286:259-70.
78. Asthma TCSotGo. A genome-wide search for asthma susceptibility loci in ethnically diverse populations. Nat Genet 1997;15:389-92.
79. Ober C, Cox NJ, Abney M, Di Rienzo A, Lander ES, Changyaleket B, et al. Genome-wide search for asthma susceptibility loci in a founder population. Hum Mol Genet 1998;7:1393-8.
80. Dizier MH, Besse-Schmittler C, Guilloud-Bataille M, Annesi-Maesano I, Boussaha M, Bousquet J, et al. Genome screen for asthma and related phenotypes in the French EGEA study. Am J Respir Crit Care Med 2000;162:1812-8.
81. Venanzi S, Malerba G, Galavotti R, Lauciello MC, Trabetti E, Zanoni G, et al. Linkage to atopy on chromosome 19 in north-eastern Italian families with allergic asthma. Clin Exp Allergy 2001;31:1220-4.
82. Matsumoto K, Schleimer RP, Saito H, Iikura Y, Bochner BS. Induction of apoptosis in human eosinophils by anti-fas antibody treatment in vitro. Blood 1995;86:1437-43.
83. Tsuyuki S, Bertrand C, Erard F, Trifilieff A, Tsuyuki J, Wesp M, et al. Activation of the fas receptor on lung eosinophils leads to apoptosis and the resolution of eosinophilic inflammation of the airways. J Clin Invest 1995;96:2924-31.
84. Walsh GM, Williamson ML, Symon FA, Willars GB, Wardlaw AJ. Ligation of CD69 induces apoptosis and cell death in human eosinophils cultured with granulocyte-macrophage colony-stimulating factor. Blood 1996;87:2815-21.
85. Alam R, Forsythe P, Stafford S, Fukuda Y. Transforming growth factor beta abrogates the effects of hematopoietins on eosinophils and induces their apoptosis. J Exp Med 1994;179:1041-5.
86. Okada S, Hagan JB, Kato M, Bankers-Fulbright JL, Hunt LW, Gleich GJ, et al. Lidocaine and its analogues inhibit IL-5-mediated survival and activation of human eosinophils. J Immunol 1998;160:4010-7.
87. Schleimer RP, Bochner BS. The effects of glucocorticoids on human eosinophils. J Allergy Clin Immunol 1994;94:1202-13.
88. Chauhan S, Leach CH, Kunz S, Bloom JW, Miesfeld RL. Glucocorticoid regulation of human eosinophil gene expression. J Steroid Biochem Mol Biol 2003;84:441-52.
89. Chen LC, Zhang Z, Myers AC, Huang SK. Cutting edge: altered pulmonary eosinophilic inflammation in mice deficient for Clara cell secretory 10-kDa protein. J Immunol 2001;167:3025-8.
90. Noga O, Hanf G, Kunkel G. Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int Arch Allergy Immunol 2003;131:46-52.
91. Kita H, Kaneko M, Bartemes KR, Weiler DA, Schimming AW, Reed CE, et al. Does IgE bind to and activate eosinophils from patients with allergy? J Immunol 1999;162:6901-11.
92. Seminario M-C, Saini SS, MacGlashan DW Jr, Bochner BS. Intracellular expression and release of Fc*RIα by human eosinophils. J Immunol 1999;162:6893-900.
93. Kozma GT, Losonczy G, Keszei M, Komlosi Z, Buzas E, Pallinger E, et al. Histamine deficiency in gene-targeted mice strongly reduces antigen-induced airway hyper-responsiveness, eosinophilia and allergen-specific IgE. Int Immunol 2003;15:963-73.
94. Drouin SM, Corry DB, Hollman TJ, Kildsgaard J, Wetsel RA. Absence of the complement anaphylatoxin C3a receptor suppresses Th2 effector functions in a murine model of pulmonary allergy. J Immunol 2002;169:5926-33.
95. Schmidlin F, Amadesi S, Dabbagh K, Lewis DE, Knott P, Bunnett NW, et al. Protease-activated receptor 2 mediates eosinophil infiltration and hyperreactivity in allergic inflammation of the airway. J Immunol 2002;169:5315-21.
96. Klion AD, Nutman TB. The role of eosinophils in host defense against helminth parasites. J Allergy Clin Immunol 2004. In press.
97. Rosenberg HF, Domachowske JB. Eosinophils, eosinophil ribonucleases, and their role in host defense against respiratory virus pathogens. J Leukoc Biol 2001;70:691-8.